Download FREE Sample
Table of Contents
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Market Forecasting
- Executive Summary
- Market Overview
-
- Market Dynamics
- Drivers
- Restraints
- Key Market Trends
- Industry Speaks
- Market Dynamics
- COVID-19 Impact on the Radioligand Therapy Market
- Global Radioligand Therapy Market - Size & Forecast (2021-2028), By Indication
- Prostate Cancer
- Neuroendocrine Tumours (NETs)
- Non-Cancerous Conditions
- Others
- Global Radioligand Therapy Market - Size & Forecast (2021-2028), By Products
- Approved Products
- Lutathera
- Zytiga
- Xtandi
- Xofigo
- Erleada
- Pluvicto
- Others
- Potential Pipeline
- Approved Products
- Global Radioligand Therapy Market - Size & Forecast (2021-2028), By End User
- Hospitals
- Clinics
- Pharmaceutical and Biotechnology companies
- Academic & Research Institute
- Others
- Global Radioligand Therapy Market - Size & Forecast (2021-2028), By Region
- North America (U.S. & Canada)
- Europe (UK, Germany, France, Italy, Spain, Rest of Europe)
- Asia Pacific (China, India, Japan, Rest of Asia Pacific)
- Rest of the World (Latin America, Middle East & Africa)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Competitive Positioning of Key Players (2022)
- Offerings Assessment, By Player
- Key Strategies Assessment, By Player (2021-2023)
- New Product & Service Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Key Companies Scanned (Indicative List)
- Johnson & Johnson Service Inc.
- Bayers Inc.
- Novartis International AG
- Amneal Pharmaceuticals LLC
- POINT Biopharma Global Inc.
- Pfizer Inc.
- Fusion Pharma
- Orano Med
- Clovis Oncology
- Telix Pharmaceuticals
- Lantheus Holdings, Inc.
- Molecular Partners
- ITM Isotope Technologies Munich SE
- Curium Pharma
- Precirix
- Radio Medix
- Other Prominent Players
